Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Sun Pharma has acquired Organon, a physician practice business in the United States, for $11.75 billion. Sun Pharma acquisitions are designed to expand global healthcare M&A capabilities by combining complementary portfolios and capabilities with Organon’s women’s health focus. Organon supports patient care through specialized physician practice offerings, strengthening Sun Pharma’s reach in key markets. The strategic acquisition is structured as a merger acquisition and covers 100% of Organon’s outstanding equity, with combined revenues expected to reach about $12.4 billion. Sun Pharma entered into a definitive agreement as a strategic buyer, targeting sustained long-term value creation through this strategic acquisition.
Source
Read full article on fortuneindia.comvia GN - entered into definitive agreement · April 27, 2026
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026